| 1 |
Editorial Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine. free! 2008
Gaffo AL, Saag KG. · No affiliation provided · Arthritis Res Ther. · Pubmed #18983690 links to free full text
Abstract: The relationship between serum urate, menopause, and aging has not been clearly defined by scientific evidence. In the present issue of Arthritis Research and Therapy, Hak and Choi present a cross-sectional analysis to clarify the effect of menopause and hormone replacement therapy on serum urate in women within the Third National Health and Nutritional Examination Survey. Menopause increased serum urate and hormone replacement therapy significantly decreased serum urate, although the overall level of change was small. The implications of these urate changes on gout and cardiovascular disease outcomes require further study.
|
| 2 |
Review Management of hyperuricemia and gout in CKD. 2008
Gaffo AL, Saag KG. · Birmingham VA Medical Center, University of Alabama at Birmingham, AL, USA. · Am J Kidney Dis. · Pubmed #18971014 No free full text.
This publication has no abstract.
|
| 3 |
Article Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares? 2009
Gaffo AL, Saag KG. · Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. · Nat Clin Pract Rheumatol. · Pubmed #19048008 No free full text.
Abstract: NSAIDs are the current mainstay of treatment for gout flares, despite being associated with an increased risk of gastrointestinal bleeding and cardiovascular events. Janssens et al. conducted a randomized, double-blind, equivalence clinical trial to determine whether the glucocorticoid prednisolone can be used as an alternative to NSAIDs in this setting. Patients referred from primary care community clinics with monosodium urate crystal-proven acute gout flares (n =120) underwent treatment with once-daily oral prednisolone 35 mg or twice-daily oral naproxen 500 mg for 5 days. The results revealed a nonsignificant difference between the two groups, both in the primary outcome measure of pain reduction and in the secondary outcomes of disability related to the affected joint and walking, suggesting equivalence between the two agents. This study helps to position oral glucocorticoids as effective and safe alternatives in the management of acute gout flares. Future studies should address the treatment of acute gout in elderly populations and in those with multiple comorbidities.
|
|
|